Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)
Agency
National Institutes of Health
Posted
Oct 6, 2026
Due Date
Sep 25, 2027
Description
<p>The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to continue the Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). CIFASD is a multidisciplinary research consortium supporting coordinated basic, clinical, translational, diagnostic, intervention, and prevention research on fetal alcohol spectrum disorders (FASD), a set of lifelong physical, cognitive, and behavioral impairments associated with prenatal alcohol exposure. The anticipated NOFO is expected to support collaborative research addressing high-priority needs in the FASD field, including improved early identification and diagnosis; development and validation of interventions; mechanistic and translational studies of prenatal alcohol exposure and alcohol teratogenesis; and approaches to reduce prenatal alcohol exposure and the incidence of FASD. Projects are expected to demonstrate integration with the broader CIFASD consortium through multidisciplinary expertise, shared resources, and coordinated data and research activities. </p>
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 364028
- Solicitation Number
- RFA-AA-28-002
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health